- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07794540
Early Versus Delayed Closure of Bladder Exstrophy in Female Patients
Primary Single-Stage Early Versus Delayed Closure of Bladder Exstrophy in Female Patients: A Randomized Controlled Trial
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Eligible phenotypic female neonates who presented with classic bladder exstrophy within the first 48 hours of life and met the prespecified clinical and anaesthetic criteria were enrolled through consecutive sampling. After written consent and baseline assessment, participants were randomized in a 1:1 ratio using a computer-generated sequence with randomly varying block sizes and stratification by centre. Allocation was implemented through sequentially numbered sealed envelopes prepared independently of recruitment.
Participants assigned to early closure underwent primary single-stage repair within 72 hours of birth. Participants assigned to delayed closure underwent the same repair at 6 to 12 weeks of age. Before delayed surgery, the exposed bladder plate was cleaned with sterile saline and covered with a clear non-adherent pad, while hydration and weight gain were monitored. The operation included closure of the bladder and posterior urethra and reconstruction of the lower abdominal wall, pelvic floor, and female external genitalia. Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension. Perioperative care was standardized in both groups.
Participants were assessed on postoperative days 7, 14, and 30. Successful bladder closure on postoperative day 30 required an intact deep bladder and abdominal-wall closure without full-thickness wound dehiscence, urinary fistula, or urinary leakage requiring repeat closure or urinary diversion. Secondary outcomes were wound dehiscence, surgical-site infection, urinary fistula, blood transfusion, reoperation, readmission, hospital stay, and adverse events. The primary analysis followed the intention-to-treat principle.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakistan
- Khyber Teaching Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Phenotypic female neonates presenting with classic bladder exstrophy within the first 48 hours of life
- Met the protocol-defined minimum birth-weight requirement
- Gestational age of at least 34 weeks
- Clinically stable and fit for general anaesthesia
- Written informed consent provided by a parent or legal guardian
Exclusion Criteria:
- Cloacal exstrophy, an exstrophy variant, or isolated epispadias
- Previous bladder or abdominal-wall surgery
- Life-threatening congenital anomaly
- Uncontrolled sepsis
- Coagulopathy
- Cardiorespiratory instability precluding surgery within the assigned window
- Parent or legal guardian unable or unwilling to comply with follow-up
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Early Closure
Participants underwent primary single-stage closure within 72 hours of birth.
|
Primary single-stage closure performed within 72 hours of birth.
The procedure included closure of the bladder and posterior urethra and reconstruction of the lower abdominal wall, pelvic floor, and female external genitalia during one anaesthetic.
Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension.
|
|
Comparatore attivo: Delayed Closure
Participants underwent primary single-stage closure at 6 to 12 weeks of age.
|
Primary single-stage closure performed at 6 to 12 weeks of age using the same operative checklist and repair.
Before surgery, the exposed bladder plate was cleaned with sterile saline and covered with a clear non-adherent pad, with monitoring of hydration and weight gain.
Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Successful Bladder Closure at Postoperative Day 30
Lasso di tempo: Postoperative day 30
|
Number and percentage of participants with an intact deep bladder and abdominal-wall closure without full-thickness abdominal wound dehiscence, urinary fistula, or urinary leakage requiring repeat closure or urinary diversion on or before postoperative day 30.
|
Postoperative day 30
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Wound Dehiscence Within 30 Days
Lasso di tempo: From surgery through postoperative day 30
|
Number and percentage of participants with partial or complete, superficial or deep disruption of the operative wound within 30 days after surgery.
|
From surgery through postoperative day 30
|
|
Surgical-Site Infection Within 30 Days
Lasso di tempo: From surgery through postoperative day 30
|
Number and percentage of participants with inflammatory signs at the operative site, with or without purulent discharge or positive culture, requiring antibiotic or surgical treatment within 30 days after surgery.
|
From surgery through postoperative day 30
|
|
Urinary Fistula Within 30 Days
Lasso di tempo: From surgery through postoperative day 30
|
Number and percentage of participants with continuous urinary leakage from the wound or another site after surgery, confirmed clinically or by imaging and requiring continued drainage or intervention.
|
From surgery through postoperative day 30
|
|
Blood Transfusion
Lasso di tempo: From the start of surgery through hospital discharge, up to 30 days after surgery
|
Number and percentage of participants who received a blood transfusion during the operative or perioperative period.
|
From the start of surgery through hospital discharge, up to 30 days after surgery
|
|
Reoperation Within 30 Days
Lasso di tempo: From surgery through postoperative day 30
|
Number and percentage of participants who underwent a repeat surgical procedure related to the primary closure within 30 days after surgery.
|
From surgery through postoperative day 30
|
|
Readmission Within 30 Days
Lasso di tempo: From discharge through postoperative day 30
|
Number and percentage of participants readmitted to hospital within 30 days after surgery.
|
From discharge through postoperative day 30
|
|
Hospital Stay
Lasso di tempo: From surgery to hospital discharge, up to 30 days after surgery
|
Duration of the index postoperative hospital stay, measured in days from surgery to discharge.
|
From surgery to hospital discharge, up to 30 days after surgery
|
|
Any Adverse Event Within 30 Days
Lasso di tempo: From surgery through postoperative day 30
|
Number and percentage of participants with at least one recorded adverse event within 30 days after surgery.
|
From surgery through postoperative day 30
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie urogenitali maschili
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Anomalie congenite
- Malattie della vescica urinaria
- Anomalie urogenitali
- Malattie e anomalie congenite, ereditarie e neonatali
- Estrofia vescicale
Altri numeri di identificazione dello studio
- KTH-BE-RCT-2021-2026
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .